Cancer-associated isocitrate dehydrogenase (IDH) 1 and 2 mutations gain a new activity of reducing α-KG to produce D-2-hydroxyglutarate (D-2-HG), which is proposed to function as an oncometabolite by inhibiting α-KG dependent dioxygenases. We investigated the function of D-2-HG in tumorigenesis using IDH1 and IDH2 mutant cancer cell lines. Inhibition of D-2-HG production either by specific deletion of the mutant IDH1-R132C allele or overexpression of D-2-hydroxyglutarate dehydrogenase (D2HGDH) increases α-KG and related metabolites, restores the activity of some α-KG-dependent dioxygenases, and selectively alters gene expression. Ablation of D-2-HG production has no significant effect on cell proliferation and migration, but strongly inhibits anchorage independent growth in vitro and tumor growth in xenografted mouse models. Our study identifies a new activity of oncometabolite D-2-HG in promoting tumorigenesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496170 | PMC |
| http://dx.doi.org/10.18632/oncotarget.3330 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
Hepatology
December 2024
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Background And Aims: Isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma (CCA) is a highly lethal subtype of hepatobiliary cancer that is often resistant to immune checkpoint inhibitor therapies. We evaluated the effects of IDH1-mutations in CCA cells on the tumor immune microenvironment and identify opportunities for therapeutic intervention.
Approach And Results: Analysis of 2,606 human CCA tumors using deconvolution of RNA-sequencing data identified decreased CD8 T cell and increased M2-like tumor-associated macrophage (TAM) infiltration in IDH1-mutant compared to IDH1-wild type tumors.
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications.
Biology (Basel)
October 2024
Upper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI 49855, USA.
In 2021, the World Health Organization classified isocitrate dehydrogenase () mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG).
View Article and Find Full Text PDFEpigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
Adv Protein Chem Struct Biol
July 2024
Computer Aided Drug Designing and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India.
Recent advances in genome-wide studies have revealed numerous epigenetic regulations brought about by genes involved in cellular metabolism. Isocitrate dehydrogenase (IDH), an essential enzyme, that converts isocitrate into -ketoglutarate (KG) predominantly in the tricarboxylic acid (TCA) cycle, has gained particular importance due to its cardinal role in the metabolic pathway in cells. IDH1, IDH2, and IDH3 are the three isomeric IDH enzymes that have been shown to regulate cellular metabolism.
View Article and Find Full Text PDFIDH inhibition in gliomas: from preclinical models to clinical trials.
Nat Rev Neurol
July 2024
Division of Neuro-Oncology, Department of Neuroscience 'Rita Levi Montalcini', University of Turin, Turin, Italy.
Article Synopsis
- Gliomas are the most common malignant brain tumors in adults and typically resist standard treatments; they often harbor mutations in the IDH1 or IDH2 genes, leading to various subtypes based on tumor grade and characteristics.
- The mutated IDH genes produce D-2-hydroxyglutarate (D-2-HG), which promotes tumor growth by causing DNA hypermethylation and disrupting the immune response.
- Recent studies, including the phase III INDIGO trial, have shown that IDH inhibitors like vorasidenib are effective in treating low-grade IDH-mutant gliomas, highlighting their potential to change treatment strategies in this area.
D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation.
Cancer Res Commun
March 2024
Department of Neurology, UCLA Medical Center, Los Angeles, California.
Unlabelled: IDH1mut gliomas produce high levels of D-2-hydroxyglutarate (D-2-HG), an oncometabolite capable of inhibiting α-ketoglutarate-dependent dioxygenases critical to a range of cellular functions involved in gliomagenesis. IDH1mut gliomas also exhibit slower growth rates and improved treatment sensitivity compared with their IDH1wt counterparts. This study explores the mechanism driving apparent reduced growth in IDH1mut gliomas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!